Compare Gilead Sciences, Inc. (GILD) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs MakeMyTrip Ltd — how do they compare? Gilead Sciences, Inc. trades at $151.28 (market cap $182.40B), while MakeMyTrip Ltd trades at $44.57 (market cap $4.09B). The key difference: Gilead Sciences, Inc. is far larger — about 44.6× MakeMyTrip Ltd's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while MakeMyTrip Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and MakeMyTrip Ltd for 12 Days on average.
| GILD | MMYT | |
|---|---|---|
Market Cap | $182.40B | $4.09B |
Volume | 4,469,821 | 1,828,010 |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $94.43 |
52-Week Low | $116.74 | $36.30 |
Typical Hold Time | 111 Days | 12 Days |
Enterprise Value | $205.46B | $4.75B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
MMYT trades at $44.33, up 2.12% today, but technical indicators signal a bearish trend. The company reported mixed quarterly earnings, with a Q1 2026 beat but Q4 2025 and Q2 2026 misses. Revenue grew to $978.34M in 2025, though net income margin remains thin at 3.23%. Analyst consensus is strongly bullish with a $77.00 price target, but institutional selling and a projected decline in 2026 cash flow pose concerns.
The stock presents a high-risk, high-reward opportunity. Strong analyst support and a potential Indian listing offer upside, but bearish technicals, earnings volatility, and rising debt-to-asset ratios in 2026 highlight significant risks. Investors should weigh the optimistic price targets against fundamental pressures and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
